An interventional study of Mindfulness Based Cognitive Therapy (MBCT) in Chemotherapy, Cancer and Chemotherapy Induced Nausea and Vomiting, sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates the effect of Mindfulness-Based Cognitive Therapy (MBCT) on chemotherapy-induced nausea and vomiting management and quality of life in oncology patients. Patients undergoing chemotherapy were allocated to either an intervention group receiving MBCT or a control group receiving routine care. The primary objective is to investigate the efficacy of the MBCT intervention in reducing nausea and vomiting symptoms and improving overall quality of life.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 54 is close to the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Saglik Bilimleri Universitesi is the lead sponsor of 456 studies on the registry; 139 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Diagnosed with cancer and scheduled to receive highly emetogenic chemotherapy.
Able to read and write.
Older than 18 years.
Able to communicate without a language barrier.
Willing to participate and provide .
No diagnosed mental or psychiatric disorder, with a (MMSE) score of 24 or higher.
Access to a device suitable for attending online sessions, such as a smartphone, computer, or tablet.
About to start a new chemotherapy regimen.
No hearing or visual impairment.
Exclusion Criteria:
Hearing impairment.
Unwilling to participate.
Intellectual disability or difficulties with comprehension.
A (MMSE) score of 23 or lower.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients participated in the Mindfullness based Cognitive Therapy Program alongside routine oncology care
Behavioral: Mindfulness Based Cognitive Therapy (MBCT)
Patients received routine oncology nursing care without MBCT sessions.
8 week structured MBCT sessisons focusing on minfullness practices, cognitive reframing and symptom awareness.
Chemotherapy induced Nausea and Vomiting Score
Assessed using the Rhodes Index of Nausea, Vomiting, and Retching (INVR). The scale consists of 8 items evaluating the duration, frequency, and distress of nausea, vomiting, and retching on a 5-point Likert scale (total score ranges from 0 to 32). Higher scores indicate greater frequency, duration, and distress caused by nausea and vomiting.
Time frame: Baseline (week 1) and post-intervention (week 9)
Quality of Life Score
Assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, Turkish version). The tool evaluates global health status, functional scales, and symptom scales. Raw scores are linearly transformed into a 0 to 100 scale. Higher scores on the global health status and functional scales represent better quality of life and higher functioning, whereas higher scores on the symptom scales represent higher levels of symptomatology/problems.
Time frame: Baseline (week 1) and post-intervention (week 9)
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Jun 2023, 4 months.
Of 1,986 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 4 months is below that.
Counting every sponsor, half of 2,061 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →